Bristol-Myers Squibb | BiCNU (Medication)
BiCNU/carmustine is indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following:brain tumors - glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors; multiple myeloma - in combination with prednisone; Hodgkin's Disease; Non-Hodgkin's lymphomas. ...
Nausea and vomiting after IV administration of BiCNU (carmustine) are noted frequently. A reversible type of hepatic toxicity, manifested by increased transaminase, alkaline phosphatase and bilirubin levels, has been reported in a small percentage of patients receiving BiCNU.
Pulmonary toxicity characterized by pulmonary infiltrates and/or fibrosis has been reported to occur from 9 days to 43 months after treatment with BiCNU and related nitrosoureas. ...
You should not receive this medication if you are allergic to carmustine or if you have any other allergies.
Inform your doctor if you have any of these other conditions:bone marrow suppression; liver disease; kidney disease; or a history of lung or breathing problems.
During pregnancy and breastfeeding is not recommended to use this medicine without your doctor's advice. ...